IL-31: A Potential Drug Target and Biomarker for Immune and Inflammatory Response Regulation

Target Name: IL31

NCBI ID: G386653

IL31

IL-31: A Potential Drug Target and Biomarker for Immune and Inflammatory Response Regulation

Interleukin 31 (IL-31) is a cytokine that plays a crucial role in the regulation of immune and inflammatory responses. It is a pro-inflammatory cytokine that is produced by various cell types in the body, including macrophages, dendritic cells, and epithelial cells. IL-31 is involved in the recruitment and activation of immune cells, as well as the regulation of cell proliferation and differentiation.

One of the key functions of IL-31 is its ability to induce the production of pro-inflammatory cytokines. These cytokines, such as TNF-伪, IL-1尾, and IL-6, are involved in the regulation of immune responses, including inflammation, fibrosis, and cancer. They are also involved in the regulation of cell survival and apoptosis.

IL-31 has been shown to have a variety of therapeutic potential, including its potential as a drug target. The ability of IL-31 to induce pro-inflammatory responses makes it an attractive target for the development of new treatments for a variety of diseases.

One of the potential mechanisms by which IL-31 may work as a drug target is its ability to modulate the activity of immune cells. IL-31 has been shown to regulate the production and function of immune cells, including natural killer cells, T-cells, and B-cells. It has also been shown to play a role in the regulation of inflammation and the regulation of cellular signaling pathways that are involved in inflammation.

IL-31 has also been shown to have a variety of potential therapeutic applications in oncology. For example, studies have shown that high levels of IL-31 are associated with the development of various types of cancer, including breast cancer, colorectal cancer, and lung cancer. Additionally, IL-31 has been shown to play a role in the regulation of cancer cell survival and the development of resistance to chemotherapy.

In addition to its potential as a drug target and its potential therapeutic applications in oncology, IL-31 is also of interest as a biomarker. The ability of IL-31 to induce pro-inflammatory responses makes it an attractive target for the development of new diagnostic tools for a variety of diseases. For example, the production of IL-31 has been shown to be involved in the development of a variety of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis.

Overall, IL-31 is a complex cytokine that plays a crucial role in the regulation of immune and inflammatory responses. Its potential as a drug target and as a biomarker make it an attractive target for the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of IL-31 in the regulation of immune and inflammatory responses and its potential as a therapeutic agent.

Protein Name: Interleukin 31

Functions: Activates STAT3 and possibly STAT1 and STAT5 through the IL31 heterodimeric receptor composed of IL31RA and OSMR (PubMed:15184896). May function in skin immunity (PubMed:15184896). Enhances myeloid progenitor cell survival in vitro (By similarity). Induces RETNLA and serum amyloid A protein expression in macrophages (By similarity)

The "IL31 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL31 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets